Tags

Type your tag names separated by a space and hit enter

Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis.
Fertil Steril. 2012 Apr; 97(4):876-85.FS

Abstract

OBJECTIVE

To evaluate the role of corifollitropin alfa, a newly developed weekly administrated long-acting recombinant FSH (rFSH), as an alternative for daily rFSH administration in women undergoing controlled ovarian stimulation in GnRH antagonist down-regulated in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles.

DESIGN

Systematic review and meta-analysis of randomized controlled trials.

SETTING

University and private centers.

PATIENT(S)

Infertile women undergoing IVF/ICSI treatment.

INTERVENTION(S)

Comparing long-acting rFSH corifollitropin alfa versus standard daily administrated rFSH in GnRH antagonist IVF/ICSI cycles.

MAIN OUTCOME MEASURE(S)

Ongoing pregnancy rate, live birth rate, clinical pregnancy rate, miscarriage rate, duration of stimulation, amount of FSH, number of retrieved oocytes, number of mature oocytes, number of embryos obtained, fertilization rate, ovarian hyperstimulation syndrome (OHSS) incidence, and adverse events. Searches (of literature through November 2011) were conducted in Medline, Embase, Science Direct, the Cochrane Library, and databases of abstracts.

RESULT(S)

Four randomized trials involving 2,326 women were included. There was no evidence of a statistically significant difference in ongoing pregnancy rate for corifollitropin alfa versus rFSH. There was evidence of increased ovarian response and risk of OHSS in corifollitropin alfa.

CONCLUSION(S)

In view of its equivalence and safety profile, corifollitropin alfa in combination with daily GnRH antagonist seems to be an alternative for daily rFSH injections in normal responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles.

Authors+Show Affiliations

Department of Obstetrics and Gynaecology, Center for Reproductive Medicine, Faculty of Medicine, Cairo University, Cairo, Egypt. m.a.youssef@amc.uva.nlNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Review
Systematic Review

Language

eng

PubMed ID

22277766

Citation

Mahmoud Youssef, Mohamed Abdelfattah, et al. "Is There a Place for Corifollitropin Alfa in IVF/ICSI Cycles? a Systematic Review and Meta-analysis." Fertility and Sterility, vol. 97, no. 4, 2012, pp. 876-85.
Mahmoud Youssef MA, van Wely M, Aboulfoutouh I, et al. Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertil Steril. 2012;97(4):876-85.
Mahmoud Youssef, M. A., van Wely, M., Aboulfoutouh, I., El-Khyat, W., van der Veen, F., & Al-Inany, H. (2012). Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. Fertility and Sterility, 97(4), 876-85. https://doi.org/10.1016/j.fertnstert.2012.01.092
Mahmoud Youssef MA, et al. Is There a Place for Corifollitropin Alfa in IVF/ICSI Cycles? a Systematic Review and Meta-analysis. Fertil Steril. 2012;97(4):876-85. PubMed PMID: 22277766.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis. AU - Mahmoud Youssef,Mohamed Abdelfattah, AU - van Wely,Madelon, AU - Aboulfoutouh,Ismail, AU - El-Khyat,Walid, AU - van der Veen,Fulco, AU - Al-Inany,Hesham, Y1 - 2012/01/23/ PY - 2011/11/05/received PY - 2012/01/01/revised PY - 2012/01/04/accepted PY - 2012/1/27/entrez PY - 2012/1/27/pubmed PY - 2012/5/31/medline SP - 876 EP - 85 JF - Fertility and sterility JO - Fertil. Steril. VL - 97 IS - 4 N2 - OBJECTIVE: To evaluate the role of corifollitropin alfa, a newly developed weekly administrated long-acting recombinant FSH (rFSH), as an alternative for daily rFSH administration in women undergoing controlled ovarian stimulation in GnRH antagonist down-regulated in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles. DESIGN: Systematic review and meta-analysis of randomized controlled trials. SETTING: University and private centers. PATIENT(S): Infertile women undergoing IVF/ICSI treatment. INTERVENTION(S): Comparing long-acting rFSH corifollitropin alfa versus standard daily administrated rFSH in GnRH antagonist IVF/ICSI cycles. MAIN OUTCOME MEASURE(S): Ongoing pregnancy rate, live birth rate, clinical pregnancy rate, miscarriage rate, duration of stimulation, amount of FSH, number of retrieved oocytes, number of mature oocytes, number of embryos obtained, fertilization rate, ovarian hyperstimulation syndrome (OHSS) incidence, and adverse events. Searches (of literature through November 2011) were conducted in Medline, Embase, Science Direct, the Cochrane Library, and databases of abstracts. RESULT(S): Four randomized trials involving 2,326 women were included. There was no evidence of a statistically significant difference in ongoing pregnancy rate for corifollitropin alfa versus rFSH. There was evidence of increased ovarian response and risk of OHSS in corifollitropin alfa. CONCLUSION(S): In view of its equivalence and safety profile, corifollitropin alfa in combination with daily GnRH antagonist seems to be an alternative for daily rFSH injections in normal responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles. SN - 1556-5653 UR - https://www.unboundmedicine.com/medline/citation/22277766/Is_there_a_place_for_corifollitropin_alfa_in_IVF/ICSI_cycles_A_systematic_review_and_meta_analysis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0015-0282(12)00121-5 DB - PRIME DP - Unbound Medicine ER -